Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H1 2018

  • ID: 4482730
  • Report
  • 112 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Abreos Biosciences Inc
  • Aeterna Zentaris Inc
  • Fountain Biopharma Inc
  • Lakewood-Amedex Inc
  • RaQualia Pharma Inc
  • Vascular BioSciences
  • MORE
Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H1 2018, provides an overview of the Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline landscape.

Cancer anorexia-cachexia syndrome or cancer cachexia is wasting of both adipose tissue and skeletal muscle in response to a malignant growth. Cachexia is present in the early stages of tumor growth before any signs or symptoms of malignancy. Symptoms include skeletal muscle wasting, weight loss and loss of appetite. Treatment includes appetite stimulants and change in life style.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Cancer Anorexia-Cachexia Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cancer Anorexia-Cachexia Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 4, 12 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.

Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Anorexia-Cachexia Syndrome (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cancer Anorexia-Cachexia Syndrome (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cancer Anorexia-Cachexia Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cancer Anorexia-Cachexia Syndrome (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abreos Biosciences Inc
  • Aeterna Zentaris Inc
  • Fountain Biopharma Inc
  • Lakewood-Amedex Inc
  • RaQualia Pharma Inc
  • Vascular BioSciences
  • MORE
Introduction

Report Coverage

Cancer Anorexia-Cachexia Syndrome - Overview

Cancer Anorexia-Cachexia Syndrome - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cancer Anorexia-Cachexia Syndrome - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cancer Anorexia-Cachexia Syndrome - Companies Involved in Therapeutics Development

Abreos Biosciences Inc

Acacia Pharma Ltd

Aeterna Zentaris Inc

Aphios Corp

Energenesis Biomedical Co Ltd

Fountain Biopharma Inc

Incyte Corp

Lakewood-Amedex Inc

NGM Biopharmaceuticals Inc

Novartis AG

Paradigm Biopharmaceuticals Ltd

RaQualia Pharma Inc

Teijin Pharma Ltd

Vascular BioSciences

Viking Therapeutics Inc

XBiotech Inc

Zeria Pharmaceutical Co Ltd

Cancer Anorexia-Cachexia Syndrome - Drug Profiles

(formoterol fumarate + megestrol acetate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

anamorelin hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-380 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVGN-7 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-1889 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAR Peptide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dronabinol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENERGIF-706 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXT-400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FB-704A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Foxo1-nRNA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Inhibit Activin A for Osteoporosis and Cancer Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IP-1510 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

macimorelin acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-1940 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NGM-120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide to Inhibit CIDEA for Cancer Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RQ-00433412 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ruxolitinib phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Cancer Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TCMCB-07 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TEISARM-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VK-5211 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Xilonix - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Z-505 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cancer Anorexia-Cachexia Syndrome - Dormant Projects

Cancer Anorexia-Cachexia Syndrome - Discontinued Products

Cancer Anorexia-Cachexia Syndrome - Product Development Milestones

Featured News & Press Releases

Mar 05, 2018: Aeterna Zentaris Provides Update on Previously Disclosed Class Action Lawsuit

Sep 15, 2017: Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride)

May 18, 2017: Helsinn Announces Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride)

Feb 13, 2017: Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen

Jun 01, 2016: Helsinn Group to Present at ASCO Pooled Follow up Efficacy Data Analysis From two Phase III Studies for Anamorelin in Cachectic Patients With Non-small Cell Lung Cancer

Feb 23, 2016: Helsinn Announces Publication of Anamorelin ROMANA 1 and ROMANA 2 Phase III Studies in The Lancet Oncology

Nov 30, 2015: Helsinn Announces European Medicines Agency Acceptance of Marketing Authorization Application for Anamorelin HCL

Oct 30, 2014: New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology

Sep 26, 2014: AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2nd Cancer Cachexia Conference

Sep 02, 2014: XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer

Apr 17, 2014: XBiotech Announces Phase I/II Study Results in Lancet Oncology

Apr 24, 2013: XBiotech Enrolls First Patient In Phase III Pivotal Trial Of Xilonix

Oct 03, 2012: XBiotech Receives Fast Track Designation From FDA For Anti-Cachexia Drug Xilonix

Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-

Mar 30, 2012: XBiotech Announces FDA Approval To Launch Phase II Study Of Xilonix As Treatment For Cachexia In Subjects With Metastatic Cancers

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Cancer Anorexia-Cachexia Syndrome - Pipeline by Abreos Biosciences Inc, H1 2018

Cancer Anorexia-Cachexia Syndrome - Pipeline by Acacia Pharma Ltd, H1 2018

Cancer Anorexia-Cachexia Syndrome - Pipeline by Aeterna Zentaris Inc, H1 2018

Cancer Anorexia-Cachexia Syndrome - Pipeline by Aphios Corp, H1 2018

Cancer Anorexia-Cachexia Syndrome - Pipeline by Energenesis Biomedical Co Ltd, H1 2018

Cancer Anorexia-Cachexia Syndrome - Pipeline by Fountain Biopharma Inc, H1 2018

Cancer Anorexia-Cachexia Syndrome - Pipeline by Incyte Corp, H1 2018

Cancer Anorexia-Cachexia Syndrome - Pipeline by Lakewood-Amedex Inc, H1 2018

Cancer Anorexia-Cachexia Syndrome - Pipeline by NGM Biopharmaceuticals Inc, H1 2018

Cancer Anorexia-Cachexia Syndrome - Pipeline by Novartis AG, H1 2018

Cancer Anorexia-Cachexia Syndrome - Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2018

Cancer Anorexia-Cachexia Syndrome - Pipeline by RaQualia Pharma Inc, H1 2018

Cancer Anorexia-Cachexia Syndrome - Pipeline by Teijin Pharma Ltd, H1 2018

Cancer Anorexia-Cachexia Syndrome - Pipeline by Vascular BioSciences, H1 2018

Cancer Anorexia-Cachexia Syndrome - Pipeline by Viking Therapeutics Inc, H1 2018

Cancer Anorexia-Cachexia Syndrome - Pipeline by XBiotech Inc, H1 2018

Cancer Anorexia-Cachexia Syndrome - Pipeline by Zeria Pharmaceutical Co Ltd, H1 2018

Cancer Anorexia-Cachexia Syndrome - Dormant Projects, H1 2018

Cancer Anorexia-Cachexia Syndrome - Dormant Projects, H1 2018 (Contd..1), H1 2018

Cancer Anorexia-Cachexia Syndrome - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abreos Biosciences Inc
  • Acacia Pharma Ltd
  • Aeterna Zentaris Inc
  • Aphios Corp
  • Energenesis Biomedical Co Ltd
  • Fountain Biopharma Inc
  • Incyte Corp
  • Lakewood-Amedex Inc
  • NGM Biopharmaceuticals Inc
  • Novartis AG
  • Paradigm Biopharmaceuticals Ltd
  • RaQualia Pharma Inc
  • Teijin Pharma Ltd
  • Vascular BioSciences
  • Viking Therapeutics Inc
  • XBiotech Inc
  • Zeria Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll